Howard Hochster

Distinguished Professor · Rutgers Health

Credentials: · · · · · · · ·

History

VEGF inhibition and renal thrombotic microangiopathy
Case report · New England Journal of Medicine · 2008 · 1,198 citations
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
New England Journal of Medicine · 2015 · 1,179 citations
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Journal of the National Comprehensive Cancer Network · 2018 · 777 citations

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $5.3M · Yale University
1997–2024
Yale Cancer Center NCTN
National Cancer Institute · U10
Contact PI · $1.7M · Yale University
2014–2019
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $283.7K · New York University School of Medicine
2008–2013
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
National Cancer Institute · R01
Contact PI · $1.8M · New York University School of Medicine
2005–2010

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Principal investigator · Recruiting · Phase 4
Rutgers, The State University of New Jersey
2025–2029
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Principal investigator · Recruiting · Phase 2
Rutgers, The State University of New Jersey
2023–2027
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
Principal investigator · Recruiting · Phase 2
Howard S. Hochster, MD
2022–2027
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
Principal investigator · Recruiting
Rutgers, The State University of New Jersey
2022–2027